Competition, page-20

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer.

The results of Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer. TLX ProstACT trial, soon to begin recruitment also with Lu177 with same endpoints. TLX591 177Lu-rosopatamab may have an advantage as I understand it is 2 administrations with a short duration apart. The competition has 4-6 administrations minimum over a 6 months period. The competition injects 5-7 times more radioactive material which has an impact on the patient, hospital, treatment environment and cost of goods.

Novartis will now file for MA, so are probably 2 years ahead of TLX.I see this as both good and bad news for TLX. Certainly good news for Illuccix if this product is used for initial imaging. Telix’s product will need to be a lot better to overcome the might of Novartis and their first mover advantage, but at least the concept is proven. I guess its a big market. Thoughts?